Nicola Tilt
About
Nicola Tilt is a scholar working on Immunology, Rheumatology and Economics and Econometrics.
According to data from OpenAlex, Nicola Tilt has authored 24 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 8 papers in Rheumatology and 5 papers in Economics and Econometrics. Recurrent topics in Nicola Tilt's work include Psoriasis: Treatment and Pathogenesis (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Nicola Tilt is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (8 papers), Rheumatoid Arthritis Research and Therapies (7 papers) and Systemic Lupus Erythematosus Research (6 papers). Nicola Tilt collaborates with scholars based in United Kingdom, United States and Belgium. Nicola Tilt's co-authors include T.G. Rowan, Martin A. Hamilton, R.G Clemence, H. A. Benchaoui, G.D. Windsor, S. Sunderland, Michael Stegemann, Patxi Sarasola, B. Poutrel and Kevin Godinho and has published in prestigious journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and Lara D. Veeken.
In The Last Decade
Nicola Tilt
24 papers receiving 303 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Nicola Tilt United Kingdom | 9 | 85 | 72 | 58 | 51 | 36 | 24 | 315 | ||
| Kieran Walshe Ireland | 7 | 15 0.2× | 22 0.3× | 32 0.6× | 56 1.1× | 44 1.2× | 12 | 308 | ||
| N. Papaioannou Greece | 11 | 48 0.6× | 70 1.0× | 11 0.2× | 43 0.8× | 56 1.6× | 31 | 318 | ||
| Harry C. Frauenfelder United States | 11 | 15 0.2× | 44 0.6× | 43 0.7× | 101 2.0× | 43 1.2× | 18 | 331 | ||
| Gültekin Atalan Türkiye | 14 | 12 0.1× | 93 1.3× | 10 0.2× | 279 5.5× | 45 1.3× | 47 | 491 | ||
| Marloes van Splunter Netherlands | 11 | 12 0.1× | 17 0.2× | 177 3.1× | 14 0.3× | 8 0.2× | 12 | 424 | ||
| E. R. Weissenbacher Germany | 12 | 202 2.4× | 40 0.6× | 34 0.6× | 3 0.1× | 7 0.2× | 30 | 509 | ||
| Giovanna Monti Italy | 16 | 6 0.1× | 206 2.9× | 32 0.6× | 29 0.6× | 51 1.4× | 31 | 775 | ||
| Gabriel Arteaga‐Troncoso Mexico | 8 | 48 0.6× | 21 0.3× | 19 0.3× | 5 0.1× | 7 0.2× | 15 | 317 | ||
| Janese Laster United States | 10 | 7 0.1× | 81 1.1× | 14 0.2× | 41 0.8× | 23 0.6× | 17 | 375 | ||
| Hirotsugu Oda Japan | 10 | 19 0.2× | 77 1.1× | 32 0.6× | 10 0.2× | 6 0.2× | 29 | 515 |
Countries citing papers authored by Nicola Tilt
Since
Specialization
Citations
This map shows the geographic impact of Nicola Tilt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Tilt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Tilt more than expected).
Fields of papers citing papers by Nicola Tilt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Nicola Tilt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Tilt. The network helps show where Nicola Tilt may publish in the future.
Co-authorship network of co-authors of Nicola Tilt
This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Tilt. A scholar is included among the top collaborators of Nicola Tilt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Tilt. Nicola Tilt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Smolen, Josef S, Peter C. Taylor, Yoshiya Tanaka, et al.. (2024). Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis. Lara D. Veeken. 63(11). 3015–3024.
2.
Merola, Joseph F., Alice B. Gottlieb, Andreas Pinter, et al.. (2024). Bimekizumab Efficacy in High-Impact Areas: Pooled 2-Year Analysis in Scalp, Nail, and Palmoplantar Psoriasis from Phase 3/3b Randomized Controlled Trials. Dermatology and Therapy. 14(12). 3291–3306.
3.
Merola, Joseph F., Curdin Conrad, Jo Lambert, et al.. (2024). Bimekizumab 3-year Efficacy in High-Impact Areas in Moderate to Severe Plaque Psoriasis: Pooled Results from Five Phase 3/3b Trials. SKIN The Journal of Cutaneous Medicine. 8(1). s304–s304.
4.
Tanaka, Yoshiya, Tsutomu Takeuchi, Derek Haaland, et al.. (2023). Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post‐hoc analysis of clinical trials. International Journal of Rheumatic Diseases. 26(7). 1248–1259.
5.
Bykerk, Vivian P., Peter Nash, David G. Nicholls, et al.. (2023). Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data. Rheumatology and Therapy. 10(3). 693–706.
6.
Merola, Joseph F., A.B. Gottlieb, Akimichi Morita, et al.. (2023). AB1089 BIMEKIZUMAB EFFICACY IN HIGH-IMPACT AREAS FOR PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: POOLED RESULTS THROUGH TWO YEARS FROM THE BE SURE AND BE RADIANT PHASE 3 TRIALS. 1766–1767.
7.
Gisondi, Paolo, Alice B. Gottlieb, Boni E. Elewski, et al.. (2022). Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology and Therapy. 13(1). 315–328.
8.
Armstrong, April W., Sandra J. McBride, Lynda Spelman, et al.. (2022). 33259 Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2). Journal of the American Academy of Dermatology. 87(3). AB175–AB175.
9.
Umezawa, Yoshinori, Akihiko Asahina, Shinichi Imafuku, et al.. (2021). Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results. Dermatology and Therapy. 11(3). 943–960.
10.
Xavier, Ricardo Machado, Yoshiya Tanaka, Zhanguo Li, et al.. (2021). CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES.
11.
Tanaka, Yoshiya, Zhijun Li, Nevsun İnanç, et al.. (2020). THU0114 CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED EFFICACY ANALYSIS OF PHASE 3 CLINICAL TRIALS ACROSS BASELINE RHEUMATOID FACTOR QUARTILES. Annals of the Rheumatic Diseases. 79. 271–272.
12.
Bailey, Kathryn, et al.. (2020). Patient Satisfaction with CIMZIA® (Certolizumab Pegol) AutoClicks® in the UK. Advances in Therapy. 37(4). 1522–1535.
13.
Bykerk, Vivian P., Alice B. Gottlieb, Kristian Reich, et al.. (2020). FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA. Annals of the Rheumatic Diseases. 79. 621–621.
14.
Poutrel, B., et al.. (2008). Evaluation of the efficacy of systemic danofloxacin in the treatment of induced acuteEscherichia colibovine mastitis. Journal of Dairy Research. 75(3). 310–318.
15.
Benchaoui, H. A., et al.. (2007). Efficacy of maropitant for preventing vomiting associated with motion sickness in dogs. Veterinary Record. 161(13). 444–447.
16.
Tilt, Nicola, et al.. (2007). Efficacy of maropitant for treatment and prevention of emesis caused by intravenous infusion of cisplatin in dogs. American Journal of Veterinary Research. 68(1). 48–56.
17.
Benchaoui, H. A., et al.. (2007). The anti‐emetic efficacy of maropitant (Cerenia™) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. Journal of Small Animal Practice. 48(2). 93–98.
18.
Godinho, Kevin, H. A. Benchaoui, Nicola Tilt, et al.. (2007). Efficacy of danofloxacin in the treatment of pneumonic pasteurellosis in specific pathogen‐free lambs. Veterinary Record. 160(22). 770–771.
19.
Windsor, G.D., et al.. (2005). Efficacy of tulathromycin in the treatment of bovine respiratory disease associated with induced Mycoplasma bovis infections in young dairy calves.. PubMed. 6(2). 96–112.
20.
Tilt, Nicola & Martin A. Hamilton. (1999). Repeatability and Reproducibility of Germicide Tests: A Literature Review. Journal of AOAC International. 82(2). 384–389.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kieran Walshe Breakdown of academic impact, for papers by N. Papaioannou Breakdown of academic impact, for papers by Harry C. Frauenfelder Breakdown of academic impact, for papers by Gültekin Atalan Breakdown of academic impact, for papers by Marloes van Splunter Breakdown of academic impact, for papers by E. R. Weissenbacher Breakdown of academic impact, for papers by Giovanna Monti Breakdown of academic impact, for papers by Gabriel Arteaga‐Troncoso Breakdown of academic impact, for papers by Janese Laster Breakdown of academic impact, for papers by Hirotsugu Oda